Figure 2.
Event-free survival was assessed for –Y (continuous line) or control (dashed line) patients previously treated (A) or treated de novo with imatinib (B). Event-free survival (C) and overall survival (panel D) were determined in patients with loss of the Y chromosome in all mitoses (ACA, continuous line), or as a clonal evolution (CE, discontinuous line) and in control (dashed line) patients. For each series the probability at five years (and standard error) are indicated.